Literature DB >> 32447333

Mucopolysaccharidosis III in Mainland China: natural history, clinical and molecular characteristics of 34 patients.

Weijing Kong1,2, Yan Meng1, Liping Zou1, Guang Yang1, Jing Wang1, Xiuyu Shi1.   

Abstract

Objectives Sanfilippo syndrome (Mucopolysaccharidosis III, MPS III) is a rare autosomal recessive hereditary disease, which is caused by lysosomal enzyme deficiency. This study was operated to investigate clinical and molecular characteristics of patients with MPS III, which will improve the diagnosis and treatment of MPS III. Method Thirty four patients with MPS III were assessed using clinical evaluation, questionnaire, and scoring system. Results Among the 34 patients, 14 had MPS IIIA, 19 had MPS III B, and one had MPS III C. Speech delay (100%) and intellectual disability (100%) were the most prevalent clinical manifestations in this cohort, followed by hyperactivity (94.12%), hirsutism (91.18%), enlarged head circumference (73.52%), repeated diarrhea (67.64%), sparse teeth (67.64%), and Mongolian spots (64.71%). There were two clinical manifestations that were significantly different between IIIA and IIIB: Hepatosplenomegaly and serrated teeth. The most common initial symptoms at diagnosis were speech delay (52.94%), hyperactivity (35.29%), and mental retardation (29.41%). Genetic analysis of 25 patients was conducted, which identified 12 novel mutations. Conclusion When language retardation, mental retardation, and rough facial features occurred, MPS III should be considered. At same time, more examination should be operated, such as examination of changes in cranial magnetic resonance imaging of cerebral cortex atrophy. Hepatosplenomegaly and serrated teeth could be used clinically to preliminarily distinguish IIIA from IIIB.

Entities:  

Keywords:  lysosomal storage disease; mucopolysaccharide storage syndrome type III; mucopolysaccharidosis III (MPS III); sanfilippo syndrome

Mesh:

Year:  2020        PMID: 32447333     DOI: 10.1515/jpem-2019-0505

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  5 in total

1.  Natural History and Molecular Characteristics of Korean Patients with Mucopolysaccharidosis Type III.

Authors:  Min-Sun Kim; Aram Yang; Eu-Seon Noh; Chiwoo Kim; Ga Young Bae; Han Hyuk Lim; Hyung-Doo Park; Sung Yoon Cho; Dong-Kyu Jin
Journal:  J Pers Med       Date:  2022-04-21

2.  What Can We Learn from the Parents of Children Affected with Mucopolysaccharidosis Type III-A in Israel?

Authors:  Shiri Liber; Orna Staretz-Chacham; Mor Kishon; Ben Pode-Shakked; Odelia Chorin; Katya Kneller; Yair Anikster; Geto Mangisto; Ann Saada; Annick Raas-Rothschild
Journal:  Mol Syndromol       Date:  2021-12-15

3.  Clinical and genetic features of 13 patients with mucopolysaccarhidosis type IIIB: Description of two novel NAGLU gene mutations.

Authors:  F Ozkinay; D A Emecen; M Kose; E Isik; A E Bozaci; E Canda; B Tuysuz; T Zubarioglu; T Atik; H Onay
Journal:  Mol Genet Metab Rep       Date:  2021-03-12

Review 4.  GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy.

Authors:  Maya Chopra; Meera E Modi; Kira A Dies; Nancy L Chamberlin; Elizabeth D Buttermore; Stephanie Jo Brewster; Lisa Prock; Mustafa Sahin
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-29       Impact factor: 5.849

Review 5.  Glaucoma in mucopolysaccharidoses.

Authors:  Weijing Kong; Jing Zhang; Cheng Lu; Yingxue Ding; Yan Meng
Journal:  Orphanet J Rare Dis       Date:  2021-07-15       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.